LPL Financial
FTXH icon

LPL Financial’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

LPL Financial’s Portfolio FTXH Stock Details FTXH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.78M Sell
151,471
-26,164
-15% -$911K ﹤0.01% 2665
2026
Q1 		$6.1M Buy
177,635
+31,530
+22% +$1.08M ﹤0.01% 2446
2025
Q4 		$4.81M Buy
146,105
+42,147
+41% +$1.31M ﹤0.01% 2566
2025
Q3 		$2.97M Sell
103,958
-5,049
-5% -$137K ﹤0.01% 2958
2025
Q2 		$2.79M Buy
109,007
+4,105
+4% +$104K ﹤0.01% 2809
2025
Q1 		$2.88M Buy
104,902
+49,026
+88% +$1.36M ﹤0.01% 2609
2024
Q4 		$1.51M Buy
55,876
+4,776
+9% +$134K ﹤0.01% 3145
2024
Q3 		$1.47M Sell
51,100
-2,015
-4% -$57.6K ﹤0.01% 3018
2024
Q2 		$1.45M Sell
53,115
-8,533
-14% -$229K ﹤0.01% 2907
2024
Q1 		$1.73M Sell
61,648
-5,769
-9% -$159K ﹤0.01% 2660
2023
Q4 		$1.79M Buy
67,417
+5,900
+10% +$149K ﹤0.01% 2501
2023
Q3 		$1.57M Sell
61,517
-9,203
-13% -$243K ﹤0.01% 2513
2023
Q2 		$1.85M Buy
70,720
+595
+0.8% +$15.7K ﹤0.01% 2320
2023
Q1 		$1.83M Sell
70,125
-2,654
-4% -$71.1K ﹤0.01% 2213
2022
Q4 		$2M Sell
72,779
-7,430
-9% -$198K ﹤0.01% 2074
2022
Q3 		$1.93M Buy
80,209
+20,540
+34% +$531K ﹤0.01% 2018
2022
Q2 		$1.58M Sell
59,669
-9,037
-13% -$239K ﹤0.01% 2212
2022
Q1 		$1.83M Buy
68,706
+8,775
+15% +$227K ﹤0.01% 2124
2021
Q4 		$1.62M Sell
59,931
-2,461
-4% -$64.6K ﹤0.01% 2249
2021
Q3 		$1.61M Sell
62,392
-1,570
-2% -$41.2K ﹤0.01% 2228
2021
Q2 		$1.66M Sell
63,962
-7,620
-11% -$197K ﹤0.01% 2130
2021
Q1 		$1.83M Buy
71,582
+6,930
+11% +$182K ﹤0.01% 1906
2020
Q4 		$1.67M Buy
64,652
+9,003
+16% +$224K ﹤0.01% 1795
2020
Q3 		$1.34M Sell
55,649
-14,490
-21% -$348K ﹤0.01% 1711
2020
Q2 		$1.6M Buy
70,139
+56,651
+420% +$1.26M ﹤0.01% 1498
2020
Q1 		$262K Sell
13,488
-324
-2% -$7.07K ﹤0.01% 2602
2019
Q4 		$322K Sell
13,812
-1,253
-8% -$27.3K ﹤0.01% 2714
2019
Q3 		$307K Sell
15,065
-401
-3% -$8.26K ﹤0.01% 2656
2019
Q2 		$327K Buy
+15,466
New +$321K ﹤0.01% 2628

Other funds holding FTXH

OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
MIM
Marshall Investment Management Littleton, Colorado $241M AUM 30.53% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
NP
Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

LPL Financial's FTXH Position: Q2 2026 in Review

LPL Financial reduced its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 15% in Q2 2026, selling an estimated $911K and leaving 151,471 shares worth $5.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2665.

LPL Financial first reported a position in FTXH in Q2 2019 and has held it in 29 quarters since. The position peaked at $6.1M in Q1 2026. 30 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

  • LPL Financial held 151,471 shares of First Trust Nasdaq Pharmaceuticals ETF worth $5.78M as of Q2 2026.
  • LPL Financial sold 26,164 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2026, an estimated $911K.
  • First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #2665 holding.
  • LPL Financial first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q2 2019 and has held it in 29 quarters since.
  • LPL Financial's First Trust Nasdaq Pharmaceuticals ETF position peaked at $6.1M in Q1 2026.
  • 30 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.